We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.
Recruitment and Active Studies
The Lakeside Healthcare Research and Innovation Unit has been set up to provide all our patients with the opportunity to take part in clinical research studies which are relevant to them.
Recruitment
MOVe-NOW clinical study
This study will be testing an investigational medicine for COVID-19.
Investigators want to see how well it may work and if it is safe in adults with COVID-19 who are more likely to have serious symptoms from COVID-19.
You may be able to take part in this study if you are 18 years or older and:
- have a health condition that may make you more likely to become very sick from COVID-19
- are not in hospital for any reason
There are more requirements, which the study doctor will discuss with you. You do not need to currently have COVID-19 to consider taking part in this study.
If you test positive for COVID-19, you will:
- be in the study for about 6 months
- visit the study clinic about 7 times
- have about 3 virtual (video or phone) visits with the study team
There is no cost to take part in this study. Reimbursement may be available for your study-related travel expenses.
To find out more, including the possible risks and benefits of being in this study, please contact us.
AstraZeneca Tharros
A Study Evaluating the Efficacy of Breztri/Trixeo on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease.
THARROS is a clinical study looking at whether treatments for COPD may help prevent COPD flare-ups and serious heart events, like heart failures and heart attacks. We understand the impact COPD has on your daily life so we’ve made it easy to get involved. You could have most of your visits over video call and get study treatment delivered to your door.
To find out more, including the possible risks and benefits of being in this study, please contact us.
Sanofi Airlympus study
The AIRLYMPUS study is testing an investigational study drug to see if it can improve breathing and symptoms of asthma and reduce future asthma attacks.
The AIRLYMPUS study is testing an investigational study drug to see if it can improve breathing and symptoms of asthma and reduce future asthma attacks when taken with standard asthma background therapy.
You may be eligible if you:
- Are 18 to 80 years of age
- Have had a diagnosis of asthma for at least 12 months
- Had at least one asthma attack in the last year
- Are taking daily treatment for your asthma
- Additional criteria apply.
If you qualify for the study you will receive study-related treatment, tests and doctor visits at no cost to you. You may be in the study for up to 64 weeks.
To find out more, including the possible risks and benefits of being in this study, please contact us.
Zenith Study
A Phase 3 global, randomized, double-blind, placebo-controlled study
A Phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Zilebesiran in addition to standard of care in reducing major adverse cardiovascular events in adult patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease .
GSK RoCCPORT
A prospective cohort study of patients with refractory or unexplained chronic cough measuring cough variability and burden on patients’ lives.
A prospective cohort study of patients with refractory or unexplained chronic cough measuring cough variability and burden on patients’ lives.
Beethoven Study
A phase 3, placebo-controlled, double-blinded, randomized study to evaluate the efficacy, safety, and tolerability of a Clostridioides difficile vaccine in adults 65 years of age and older
A phase 3, placebo-controlled, double-blinded, randomized study to evaluate the efficacy, safety, and tolerability of a Clostridioides difficile vaccine in adults 65 years of age and older
Clinical Trial for an Investigational Bird Flu Vaccine
Moderna is looking for individuals 18 years of age or older to take part in a clinical trial of an investigational vaccine for the pandemic bird flu, H5N1, a form of influenza A.
A pandemic flu is a global outbreak of an influenza virus that most people lack immunity to. Compared to the seasonal flu, this pandemic bird flu may spread more rapidly and cause more severe symptoms.
The Odyssey 301 Trial is helping researchers learn more about Moderna’s investigational pandemic bird flu vaccine, known as mRNA-1018-H5 which may potentially help protect people from getting sick if they come into contact with the virus.
Trial participation
Participation in this study will last approximately 7 months and includes about 5 in-clinic visits and 4 safety follow-up phone calls. Clinic visits will occur during screening (between Days −14 and 0), on Day 1 (Baseline), Day 22, Day 43, and Day 205. Additional unscheduled visits may occur if needed. Safety follow-up calls will take place on Days 8, 29, 50 and 112.
Participants will receive 2 study injections, given on Day 1 (Baseline) and Day 22. This is a blinded study, meaning neither you nor the study doctor will know which study intervention you receive.
Participants will be asked to use an electronic diary (eDiary) to record any expected side effects for 7 days after each study injection. Information about any unexpected side effects will be collected from the first injection through 28 days after the second injection. Certain adverse events, including those leading to discontinuation, events of special interest, and medically attended adverse events, will be monitored from Day 1 through the end of the study on Day 205. Serious adverse events will be monitored from the time you sign the informed consent form through the end of the study.
The purpose of this study is to evaluate the immune response after 2 doses of the investigational vaccine mRNA-1018-H5 and to assess its safety and tolerability in adults 18 years of age and older.
Interested individuals must
- Be 18 years of age or older
- Be in generally good health including well controlled chronic conditions
- NOT have received any other vaccines within 28 days before the trial injections
More criteria apply, which the trial doctor can explain to anyone who is interested.
About bird flu
H5 “bird flu” is a virus that causes outbreaks in birds, particularly poultry. It has also been found in other animals such as cows. People can become infected through close contact with infected animals, their droppings, or by breathing in the virus particles in contaminated environment. In people, symptoms have most commonly been mild and may include eye redness/irritation, fever, cough, headache, sore throat, tiredness, and muscle aches. In some cases, people may develop more serious symptoms such as shortness of breath or difficulty breathing, confusion and seizures and may need care in a hospital.
Interested in joining this trial?
Current Studies
Lakeside Healthcare Research and Innovation Unit
- AstraZeneca Flash - A Phase 2a, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of Atuliflapon given orally once daily for twelve weeks in adults with moderate-to-severe uncontrolled asthma.
- AstraZeneca Prospero - A Phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled extension study to evaluate the long-term efficacy and safety of Tozorakimab in participants with chronic obstructive pulmonary disease (COPD) with a history of COPD exacerbation.
- AstraZeneca SOLSTICE - A Phase IIb, randomized, double-blind, placebo-controlled, and open-label active comparator study to evaluate the efficacy, safety, and tolerability of AZD5004 in adults with type 2 diabetes mellitus.
- Bellus Calm-1 - A Phase 3, 52-week, randomized, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open-label extension of BLU-5937 in adult participants with refractory chronic cough, including unexplained chronic cough.
- Moderna CMVictory - A phase 3 vaccine study. Testing a new investigational vaccine (mRNA-1647) for its safety and effectiveness in preventing CMV in healthy adult females.
- Moderna Nova - A Phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the safety and efficacy of mRNA-1403, a multivalent candidate vaccine to prevent norovirus acute gastroenteritis in adults aged ≥18 years
- MSD MK00616-015 - A Phase 3, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of MK-0616 in reducing major adverse cardiovascular events in participants at high cardiovascular risk.
- Novartis Victorion - 1 Prevent - A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients.
- Novo Nordisk Zeus - A research study to look at how Ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation.
- Nova 301 - This trial will see if an investigational vaccine can protect people 60 years of age or older against symptoms caused by the norovirus stomach bug.
- Amgen Asthma - A phase 2 study of Rocatinlimab in moderate -to- severe asthma in Adults
- Bellus Calm 2 - The CALM-2 Study is looking at a potential new drug (an investigational drug) for the treatment of refractory chronic cough (RCC), including unexplained chronic cough.